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Summary
Different models to investigate the prognosis of peripheral T cell lym-
phoma not otherwise specified (PTCL-NOS) have been developed by
means of retrospective analyses. Here we report on a new model designed
on data from the prospective T Cell Project. Twelve covariates collected by
the T Cell Project were analysed and a new model (T cell score), based on
four covariates (serum albumin, performance status, stage and absolute
neutrophil count) that maintained their prognostic value in multiple Cox
proportional hazards regression analysis was proposed. Among patients reg-
istered in the T Cell Project, 311 PTCL-NOS were retained for study. At a
median follow-up of 46 months, the median overall survival (OS) and pro-
gression-free survival (PFS) was 20 and 10 months, respectively. Three
groups were identified at low risk (LR, 48 patients, 15%, score 0), interme-
diate risk (IR, 189 patients, 61%, score 1–2), and high risk (HiR, 74
patients, 24%, score 3–4), having a 3-year OS of 76% [95% confidence
interval 61–88], 43% [35–51], and 11% [4–21], respectively (P < 0001).
Comparing the performance of the T cell score on OS to that of each of
the previously developed models, it emerged that the new score had the
best discriminant power. The new T cell score, based on clinical variables,
identifies a group with very unfavourable outcomes.
Keywords: PTCL-NOS, prognostic index, survival, risk factors, clinical
variables.
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Peripheral T cell lymphomas (PTCLs) comprise a heteroge-
neous group of neoplasms reflecting the diverse cells of ori-
gin (post-thymic lymphoid cells at different stages of
differentiation) (Jones et al, 2000; Swerdlow et al, 2008),
with different morphological patterns, phenotypes and clini-
cal presentations, and account for 5–10% of all lymphopro-
liferative disorders in Western countries.
The overall incidence is 05–2 per 100 000 persons per
year, with a striking epidemiological distribution (Vose et al,
2008; Bellei et al, 2012).
The 2008 World Health Organization (WHO) classifica-
tion broadly divides PTCLs into four categories, into
which subtypes can be further distinguished based on their
clinical, immunophenotypical, morphological and biologi-
cal features, overall characterized by aggressive clinical
course and poor response to therapy (Swerdlow et al,
2008).
The most frequent subtype of PTCLs is PTCL, not other-
wise specified (PTCL-NOS) a basket term when features do
not conform to known entities within the 2008 WHO classi-
fication.
The prognosis of patients with PTCL-NOS is poor, and
optimal therapy remains challenging. With standard anthra-
cycline-based therapy, the complete response rate ranges
from 40% to 60%, with overall survival (OS) of 30–40%
(Gallamini et al, 2004; Weisenburger et al, 2011).
The many studies performed to assess the contribution of
clinical and biological factors in influencing the prognosis of
PTCL-NOS reported that poor Eastern Cooperative Oncol-
ogy Group performance status (ECOG-PS), advanced stage,
presence of extranodal sites, bulky disease, high lactate dehy-
drogenase (LDH) levels and Ki67 rate were significantly cor-
related with shorter OS (Gallamini et al, 2004; Went et al,
2006; Weisenburger et al, 2011).
The usefulness of the International Prognostic Index (IPI),
developed for diffuse large B cell lymphoma (DLBCL), has
also been investigated and confirmed for PTCL-NOS (Gal-
lamini et al, 2004; Weisenburger et al, 2011).
To better define the clinical outcome of PTCL-NOS, the
Intergruppo Italiano Linfomi (now Fondazione Italiana lin-
fomi, FIL) performed a large study on 385 patients diagnosed
and treated in the 1990s and defined a prognostic model, the
Prognostic Index for PTCL-unspecified (PIT), in which age
(<60 years), ECOG PS 2 or higher, LDH level above upper
normal range, and bone-marrow involvement were indepen-
dent predictors of OS (Gallamini et al, 2004).
The PIT stratified the patients into four distinct groups
with differing risk: low (no adverse factors), intermediate
(1 adverse factor) intermediate-high (2 adverse factors) and
high (3–4 adverse factors), with a 5-year OS of 623%,
529%, 329% and 183%, respectively (P < 00001).
The PIT was slightly more effective than the IPI in strati-
fying patients (Gallamini et al, 2004).
An updated version of the PIT (m-PIT) was proposed, in
which bone marrow involvement was replaced by Ki67 rate
of expression, resulting in a more robust tool than the PIT
(Went et al, 2006).
The most recent efforts to improve the understanding of
clinical prognostic factors in PTCL-NOS were undertaken by
the International Peripheral T cell Lymphoma Project
(IPTCLP) on a sample of 340 cases diagnosed between 1990
and 2002: both the PIT and the IPI remained highly signifi-
cant for both OS and progression-free survival (PFS)
(P < 0001) (Weisenburger et al, 2011). In univariate analy-
sis, the presence of B-symptoms, bulky disease ≥10 cm, ele-
vated serum C-reactive protein, a high number of
transformed tumour cells, and platelet count less than
150 9 109/l adversely affected both OS and PFS; in multiple
Cox proportional hazards (PH) regression analysis controlled
for IPI, only bulky disease remained predictive for both OS
and PFS, and thrombocytopenia for PFS (Weisenburger et al,
2011).
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A common limitation of the latter studies is their retro-
spective nature.As a result, data have spanned several years,
not been collected on consecutive cases, and do not account
for changes in the classification systems (Gallamini et al,
2004; Weisenburger et al, 2011).
To evaluate prognosis prospectively, the IPTCLP estab-
lished the T Cell Project, which collects an exhaustive set of
clinical data and biological information. Herein we report on
the analysis of prognostic factors performed on a cohort of
506 cases of PTCL-NOS collected in the prospective T Cell
Project.
Methods
Patients and methods
The T Cell Project (NCT01142674) was incepted in September
2006 as a prospective registry of patients with PTCL-NOS,
angioimmunoblastic T cell lymphoma (AITL), anaplastic large
cell lymphoma (ALCL) and all of the rarer subtypes of nodal
and extranodal aggressive histologies of PTCL.
Data collection was accomplished via electronic case
report forms using a dedicated website (www.tcellproject.org)
with adoption of the proper technology to ensure protection
of the data of individual subjects in web communications.
The study was conducted in compliance with the Helsinki
Declaration, was approved by the appropriate research Ethics
Committees/Institutional Review Boards and required each
patient to consent in written prior to registration.
Most of the cases from the T Cell Project and the COM-
PLETE Registry (NCT01110733) underwent a central review
of initial diagnosis, as per protocol.
Statistical methods
To determine the required PTCL-NOS sample size, we ini-
tially assumed that each risk factor had a prevalence of at
least 10%, the 5-year survival rate of the entire study popula-
tion was 45%, and the hazard ratio (HR) would be two with,
as compared to without, the risk factor.
Under these conditions, there would be an 80% power to
detect a statistically significant effect of the risk factor on
outcome endpoint with a sample size of 460 patients with
PTCL-NOS, allowing an inter-relationship between risk fac-
tors in multivariate analysis.
For the development of the prospective alternative prog-
nostic model we included 12 variables selected from those
reported in the literature to impact on survival of PTCL-
NOS, including clinical (ECOG PS, Ann Arbor stage,
B-symptoms, number of extra-nodal sites), biological [LDH,
albumin serum level, platelet count, haemoglobin level, lym-
phocyte/monocyte ratio (LMR), neutrophil/lymphocyte ratio
(NLR)] and demographic (age, sex) factors.
The main endpoint of the study was OS, measured from
the date of diagnosis until death from any cause or date of
last know contact for living patients (Cheson et al, 1999).
The secondary endpoint was PFS, defined as the time from
diagnosis to progressive disease or death from any cause. OS
and PFS were calculated using Kaplan–Meier estimators,
comparison between categories performed by the log-rank
test and Cox PH regression, and the effect of the covariates
reported as HR with 95% confidence interval (95 CI).
Continuous biological covariates were dichotomized
according to usual clinical thresholds, except for NLR, that
was modelled as a continuous covariate in an explorative
Cox PH cubic spline analysis (Royston, 2000) adjusted by
IPI; the degrees of freedom for NLR was selected on the basis
of the minimum Akaike information criterion (AIC; Akaike,
1974).
The final model obtained from Cox PH regression
included four covariates that showed negligible difference
between log-likelihood if compared with the full model
including all 12 covariates.
The influence of measure for the effect of a single subject
on the overall coefficient vector was checked by means of the
likelihood displacement.
The proportionality of the hazard risk was graphically
checked using the scaled Schoenfeld residuals method
(Schoenfeld, 1982). All P values were two sided.
Performance of indices was compared by a measure of
global fit (AIC; Akaike, 1974), and by a measure of concor-
dance index (c-Harrell) (Harrell, 2001), with low values of
AIC indicating better fit and high c-Harrell values indicating
better discrimination.
An external validation sample of patients with newly diag-
nosed PTCL-NOS registered in the COMPLETE Registry
(NCT01110733) was used to further validate the predictive
model.
The statistical analyses were performed using Stata version
140 or later (StataCorp. LLC, College Station, TX, USA), R
version 3.3.0 or later (R Core Team 2016), and the ‘rms’
package for R (Harrell, 2016), version 4.4-2 or later. P values
<005 were considered statistically significant.
Results
Patient characteristics and treatment
Between September 2006 and October 2015, 506 cases of
potentially assessable PTCL-NOS were registered, and a total
of 311 PTCL-NOS patients (61%) were retained for develop-
ing the prognostic model (Fig 1); the list of the investigated
covariates and their characteristics in the study cohort are
summarized in Table I.
The median age was 63 years (range 23–83), 62% of
patients were male, and advanced stage disease was found in
76%.
Most patients of the study sample were from Europe
(n = 157, 50%), followed by South America (n = 70, 23%),
United States (n = 59, 19%) and Asia (n = 25, 8%).
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The majority of patients were classified as low/low-inter-
mediate risk according to each of the indices previously
reported that were applied: IPI 53%, PIT 53% (Gallamini
et al, 2004), IPTCLP 75% (Weisenburger et al, 2011) and m-
PIT 88% Went et al, 2006), respectively.
Overall, 246 patients (79%) received systemic therapy with
curative intent: of these 246 patients, 182 (74%) were treated
with CHOP (cyclophosphamide, doxorubicin, vincristine,
prednisolone)/CHOP-like and 31 patients (13%) 43 (18%)
with etoposide-containing (CHOEP/CHOEP-like) regimens;
and 21 (9%) patients received other different regimens; Ten
patients (4%) had a satisfactory initial response and were
consolidated by stem cell transplant, with some geographical
variations (Europe 46%, USA 89%, South America 18%,
Asia 00%).
At a median follow-up of 46 months (range 1–99), 170
deaths were recorded, most due to lymphoma (70%), followed
by infection (9%), treatment toxicity (8%) or other (13%).
The 3-year and 5-year OS was 41% [95 CI 34–47] and
32% [95 CI 26–38], respectively, with a median OS of
20 months; the OS of the 189 cases excluded due to missing
covariates was superimposable to that of study sample, sug-
gesting a lack of selection bias (P = 0431). The 3-year and
5-year PFS was 28% [95 CI 23–34] and 23% [95 CI 18–29],
respectively, with a median PFS of 10 months (Fig 2).
Prognostic model development
In univariate analysis, all the analysed variables had a statisti-
cally significant impact on OS (Table II).
The 170 reported events correspond to an event/variable
ratio of 14/1, which was acceptable to perform the multivari-
ate analysis (Harrell et al, 1984; Smith et al, 1992); risk
groups were defined by comparing the relative risk of death
in patients with each possible number of presenting risk fac-
tors and combining the categories with a similar relative risk.
Assessable
PTCL-NOS
N = 506
Retained for model development
N = 311 (61%)
Incomplete availability of 
investigated covariates n = 189
Inadequate follow-up n = 6
Remaining sample
PTCL-NOS
N = 500
Missing covariates (n = 189 Patients)
Age > 60 years 0%
Sex, male 0%
Stage III-IV 44%
B-symptoms 24%
Extra nodal sites >1 49%
ECOG PS >1 25%
LDH > ULN 50%
Hb < 120 g/l 31%
Albumin < 35 g/l 50% 
Platelet count < 150 x 109/l 31%
NLR > 6·5 36%
ANC > 6·5 x 109/l 35%
LMR  2·1 52%
Fig 1. Flow chart of patients included in the
analysis. ANC, absolute neutrophil count;
ECOG-PS, Eastern Cooperative Oncology
Group performance status; Hb, haemoglobin;
LMR, lymphocyte to monocyte ratio; NLR,
neutrophil to lymphocyte ratio; PTCL-NOS,
peripheral t- cell lymphoma, not otherwise
specified; ULN, upper limit of normality; LDH,
lactated dehydrogenase.
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From multiple Cox PH regression analysis four factors
were predictive of OS: stage, ECOG-PS, serum albumin level
and absolute neutrophil count (ANC) (Table II).
The prognostic model (T cell score) was developed con-
sidering each adverse factor as having weight = 1, and identi-
fied three groups at different risk: low-risk (LR, 48 patients,
15%, score zero), intermediate risk (IR, 189 patients, 61%,
score one or two), and high-risk (HiR, 74 patients, 24%,
score three or four).
The three risk groups had a 3-year and 5-year OS of 76%
[95 CI 61–88] and 69% [95 CI 49–83], 43% [95 CI 35–51]
and 31% [95 CI 23–40], 11% [95 CI 4–21] and 8% [95 CI
2–18] for patients at LR, IR and HiR respectively
(P < 0001) (Table III and Fig 3A).
The model also proved to be a robust tool for PFS: the
5-year PFS was 52% [95 CI 33–67], 22% [95 CI 16–30] and
7% [95 CI 2–16] in LR, IR and HiR, respectively (P < 0001;
data not shown).
External validation
In view of the fact that some US Institutions participated in
both the T Cell Project and the COMPLETE registry, a pre-
liminary crosscheck was performed to exclude the COM-
PLETE registry cases that were used for the T cell score
development from the validation sample: 98 patients
remained available for the validation, with a median age of
61 years (range 24–90), 65% male, 76% presented with
advanced stage.
The median follow-up of the validation cohort was
18 months (range 0–68), and 52 events for survival (53% of
patients) were recorded: due to the shorter follow-up of the
validation sample, 3-year OS is presented, which was 43%
[95 CI 33–55] for the entire cohort, with a median OS of
23 months.
Applying the model in the validation sample, multiple
Cox PH regression analysis stratified the patients as follows:
LR, 18 patients (18%); IR, 54 patients (55%); HiR, 26
patients (27%): the 3-year OS of the three groups was 69%
[95 CI 46–100], 41% [95 CI 29–57] and 31% [95 CI 17–57]
for the LR, IR and HiR, respectively (P = 002) (Table III
and Fig 3B).
Notably, the distribution of the different risk groups was
superimposable in the training and validation samples, being
15% and 18% in LR, 61% and 55% in IR, and 24% and
27% in HiR, respectively, and the discriminant power
between the two groups was also comparable, with c-Harrell
Table I. Baseline characteristics of the patients of the training sample
(n = 311) including variables with possible impact on survival anal-
ysed.
Factor N %
Median age, years (range) 63 (23–83)
Age >60 years 170 55
Sex, male 192 62
Stage III–IV 237 76
B-symptoms presence 136 44
Extra nodal sites >1 88 28
ECOG PS >1 81 26
LDH > ULN 164 53
Hb < 120 g/l 122 39
Albumin < 35 g/l 118 38
Platelet count < 150 9 109 cells/l 65 21
NLR > 65 64 21
ANC > 65 9 109/l 73 23
LMR ≤ 21 129 41
ANC, absolute neutrophil count; ECOG-PS, Eastern Cooperative
Oncology Group performance status; Hb, haemoglobin; LDH, lactate
dehydrogenase; LMR, lymphocyte to monocyte ratio; NLR, neu-
trophil to lymphocyte ratio.
Fig 2. Kaplan–Meier curves of overall survival
and progression-free survival (for all patients
in the training sample (n = 311). 95% CI, 95%
confidence interval; OS, overall survival; PFS,
progression-free survival.
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Table II. Univariate and multivariate Cox PH regression in the training sample (n = 311).
5-year OS [95 CI] Univariate Multivariate*
Overall (n = 311) 32 [26–38]
Factor Status HR [95 CI] HR [95 CI] P-value
Stage I–II 52 [37–65] 100 100
III–IV 25 [18–33] 216 [143–327] 174 [114–265] 0010
ECOG PS 0–1 38 [30–46] 100 100
2–4 15 [7–25] 262 [191–361] 212 [152–294] <0001
Albumin, g/l ≥35 42 [34–52] 100 100
<35 15 [8–24] 266 [196–361] 203 [147–281] <0001
ANC, 9109/l ≤65 38 [30–45] 100 100
>65 13 [5–26] 205 [148–285] 185 [133–258] <0001
NLR ≤65 37 [30–45] 100
>65 13 [5–24] 223 [160–312]
Age, years ≤60 39 [30–48] 100
>60 26 [18–35] 125 [092–170]
Sex Female 43 [31–54] 100
Male 26 [19–34] 154 [111–214]
B-symptoms No 42 [33–51] 100
Yes 18 [11–27] 179 [132–243]
ENS, n 0–1 32 [24–40] 100
>1 31 [21–42] 119 [086–165]
LDH ≤ULN 44 [34–54] 100
>ULN 21 [14–29] 199 [146–273]
Hb, g/l ≥120 37 [28–45] 100
<120 26 [17–35] 143 [106–195]
Platelet count, 9109/l ≥150 34 [27–42] 100
<150 23 [12–36] 154 [108–220]
LMR >21 37 [28–46] 100
≤21 25 [16–34] 153 [113–208]
Slope shrinkage 0955 (overfitting 0045). c-Harrell 0706 (corrected 0700). Log-likelihood test final model versus full model, P = 0273. Final
model included 310 cases: one subject removed because of an influential point on the coefficient vector. Slope shrinkage and corrected c-Harrell
over 250 bootstrap replicates. 95 CI, 95% confidence interval; Cox PH, cox proportional hazard regression, Efron method for ties; ECOG-PS,
Eastern Cooperative Oncology Group performance status; ENS, extranodal sites; Hb, hemoglobin; HR, hazard ratio; LDH, lactated dehydrogenase;
LMR, lymphocyte monocyte ratio; NLR, neutrophil lymphocyte ratio; PS, performance status; ULN, upper limit of normality.
*Final model estimated in sample of 310 patients, one excluded because it was an outlier. Median follow-up 46 months (range 1–99 months).
Table III. Distribution of patients with PTCL-NOS by risk score in the training sample (n = 311) and in the external validation sample (n = 98).
Training sample
Risk (score) N % Events 3-year OS [95 CI] HR [95 CI] P-value
Low (0) 48 15 12 76 [61–88] 100
Intermediate (1–2) 189 61 100 43 [35–51] 308 [165–576] <0001
High (3–4) 74 24 58 11 [4–21] 888 [462–171] <0001
High versus Intermediate 288 [207–400] <0001
c-Harrell 0674
Median follow-up: 46 months (range 1–99 months)
External validation sample
Low (0) 18 18 5 69 [46–100] 100
Intermediate (1–2) 54 55 30 41 [29–57] 227 [088–585] 0091
High (3–4) 26 27 17 31 [17–57] 380 [140–103] 0009
c-Harrell 0631
Median follow-up: 18 months (range 0–68 months)
95 CI, 95% confidence interval; HR, hazard ratio; OS, overall survival; PTCL-NOS, peripheral t- cell lymphoma, not otherwise specified.
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0674 and 0631 in the training and validation samples,
respectively.
The Kaplan-Meier curves for LR and IR were similar in
the two cohorts. However, HiR patients had an apparent bet-
ter survival in the external validation cohort (3-year OS 27%
vs. 11% and HR = 380 vs. 888) (Fig 3).
Discussion
The prognosis of PTCL-NOS is poor, for both the first line
and salvage settings. There is consequently an urgent need to
risk stratify the affected patients through accurate prognostic
models. Among all the previously reported indices, IPI and
PIT are the most commonly used. Notably, there is a
considerable overlap in parameters used to build all the vari-
ous models, all developed based on retrospective data collec-
tions.
The present study proposes a new model (T cell score)
that is able to stratify patients into three groups with differ-
ing risk, which was developed in a subset of 311 patients
with PTCL-NOS prospectively registered in the T Cell Project
starting from 12 covariates with a significant impact on OS
in univariate analysis, and based on the four covariates that
maintained their impact in multivariate analysis (serum albu-
min level, (ANC), ECOG-PS and stage).
ECOG-PS and stage were previously well recognized as
having a prognostic impact in PTCL by a series of authors
(Lopez-Guillermo et al, 1998; Savage et al, 2004; Lee et al,
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Figure 3. Kaplan–Meier curves of overall sur-
vival by risk groups identified by the model in
the training sample (n = 311) (Panel A) and in
the validation sample (n = 98) (Panel B).
Interm., intermediate.
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2009), and indeed they were already included in previously
reported indices (Gallamini et al, 2004; Went et al, 2006;
Weisenburger et al, 2011), showing them to be highly signifi-
cant predictors for both OS and PFS.
In recent years, low serum albumin was reported to have
an adverse prognostic impact on OS in PTCL, both in uni-
variate analysis (Watanabe et al, 2010) and as an indepen-
dent predictor (Chihara et al, 2009; Raina et al, 2010).
There is increasing and consistent evidence in recent liter-
ature that cancer-associated inflammation is a key determi-
nant of outcome in patients with cancer (Mantovani et al,
2008; Grivennikov et al, 2010; Gu et al, 2016). One routinely
available marker of the systemic inflammatory response is
the NLR. A single institution experience reported on 119
mycosis fungoides (MF) patients having a NLR of
207  117 compared to 176  053 for the control group
(P < 005), confirming that a high NLR at MF diagnosis rep-
resents a simple, poor prognostic factor for identifying high-
risk patients with MF (Cengiz et al, 2017). Recently, Beltran
et al (2016) retrospectively evaluated 83 PTCL-unspecified
patients in terms of NLR, and reported that in multivariate
analyses, a NLR ≥ 4 was independently associated with worse
OS after adjustment for the IPI and the PIT scores.
Chen et al (2014) correlated elevated ANC levels
(>73 9 109/l) to an inferior OS (P = 0017, HR 156) in
multivariate analysis on 817 treatment-na€ıve DLBCL regis-
tered in the MD Anderson Cancer Center lymphoma data-
base; additionally, Spassov et al (2015) retrospectively
reviewed the clinical outcome of 174 R-CHOP treated pri-
mary nodal DLBCL, and they found an inferior OS was sig-
nificantly associated with decreased albumin (≤394 g/l,
P < 0001) and elevated ANC (>519 9 109/l, P = 0011)
which was confirmed in multivariate analysis.
Our analyses demonstrated that ANC strongly correlated
with NLR, with 92% of the cases in our cohort classified into
the same risk group (K statistics 0854; P < 0001) when
using either the NLR or ANC; thus, ANC was retained
instead of NLR in the analysis (Table II).
To date, the innate mechanisms of tumour pathogenesis
and progression remains unclear. However, several studies
have indicated that tumour pathogenesis and progression are
closely associated with the tumour microenvironment.
Recent studies have suggested that a systemic inflammatory
state is associated with the malignant biological behaviour of
the tumour. In particular, elevated ANC has been found as a
predictor of poor prognosis in various types of tumours,
including gastric, colorectal, pancreatic, breast and lung can-
cers and Hodgkin Lymphoma.
Considering the OS of the different risk groups identified
by the T cell score, patients with a score zero, i.e. none of the
four adverse prognostic factors (15% of the cohort) had a
5-year OS of 69%, i.e. a better outcome with respect to
patients reported at low-risk by previous indices. The T cell
score also identified a group with very unfavourable risk, with
a score of 3–4 (24% of the patients), and a 5-year OS of 8%.
The external validation was performed on 98 patients with
PTCL-NOS registered in the COMPLETE registry: the valida-
tion and training samples had similar patient characteristics,
showed a homogeneous distribution of risk groups, and had
a superimposable discriminant power, as suggested by the
c-Harrell values and by a P = 002.
Outcomes for the LR and the IR groups were superimpos-
able in the training and the external validation sample, while
in the latter a better OS for HiR group was recorded; this
might be due to the large differences between the training
and the external validation sample in median follow-up (49
vs. 18 months, respectively) and the numeric difference (331
vs. 98 patients, respectively).
Frontline therapy was homogeneous in our cohort with
>80% receiving anthracycline-based therapy; however, given
that therapy influences significantly prognostic factors, the
score will need to be validated as new therapies evolve.
In the analysis conducted by the IPTCLP (Weisenburger
et al, 2011), Ki67 proliferation index, transformed tumour
cells, Epstein–Barr virus (EBV)-encoded small RNA-positive T
cells, CD56 and CD30 expression were also found to be adverse
prognostic factors both for OS and PFS in univariate analysis,
while multivariate analysis controlling for the IPI, only trans-
formed cells >70% was predictive for OS, and no pathological
feature was predictive for PFS; in the 311 patients used as
training sample for the T cell score, CD30 expression was avail-
able in 43% of our patients, thus precluding its incorporation
in the model development; however, the analysis performed
regarding the impact of CD30 expression on OS in the avail-
able cases did not lead to a significant difference (P = 0428).
The pattern of expression of T cell helper type 1 (Th1)- or
type 2 (Th2)-associated antigens or activated T-cell receptor
evaluated in a series of T cell Non-Hodgkin lymphoma
patients allowed the identification of subgroups of PTCL-
NOS patients with different probabilities of survival: in par-
ticular, patients with PTCL-NOS expressing one of Th1 or
Th2 antigens tended to show favourable prognosis as com-
pared with cases not expressing Th1 or Th2 antigens (Tsu-
chiya et al, 2004); moreover, the recently revised 2016 WHO
classification (Swerdlow et al, 2016) recognizes a category
with a T follicular helper type phenotype that includes prior
cases of PTCL-NOS as defined by the WHO 2008 clasifica-
tion (Swerdlow et al, 2008).
Finally, gene expression profiling studies have reported
reclassification of 37% morphologically diagnosed PTCL-
NOS cases into other subtypes (Iqbal et al, 2014); in the
remainder of the cases two major subgroups were identified
by either high expression of GATA3 or TBX21 with the for-
mer associated with a poor OS, and high expression of a
cytotoxic gene-signature within the TBX21 subgroup showing
poor clinical outcome.
Like previous models, the new T cell score it is also based
only on clinical variables, and does not account for differ-
ences bought about by the new molecular and genotypic find-
ings, which could have potential clinical relevance (Table SI).
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In conclusion, although the IPI, PIT, IPTCLP and m-PIT
still remain useful in defining risk for PTCL-NOS, the T cell
score, developed on a prospectively collected data set, better
stratifies patients and has the best performance compared to
the other indices; further studies implementing some of the
emerging biological variables to clinical factors, need to be
performed to determine if clinical risk can be further refined
and allow for better risk stratification.
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